Investors Can’t Help Gorging on Anti-Obesity Drugs
Investors’ appetite for obesity treatments is proving hard to satisfy. Swiss pharmaceuticals giant Roche Holding AG has just agreed to pay up to $3.1 billion for a US biotech working on several early-stage........